Hepatocellular Carcinoma in Children: Results of the First Prospective Study of the International Society of Pediatric Oncology Group

Czauderna, Piotr; MacKinlay, Gordon A.; Perilongo, Giorgio; Brown, Julia; Shafford, E.; Aronson, Daniël C.; Pritchard, Jon; Chapchap, Paulo; Keeling, Jean W.; Plaschkes, J.; Otté, Jean-Bernard

doi:10.1200/jco.2002.06.102

Cited by 250 publications

(256 citation statements)

References 30 publications

Supporting

Mentioning

233

Contrasting

Unclassified

Order By: Relevance

“…2017; 17(8):e11837. Many of the previous studies have reported chronic hepatitis B related cirrhosis as the most common underlying cause of pediatric HCC (14), however, we didn't have any case of HBV related cirrhosis in these 30 cases of pediatric HCC. We believe it is due to extensive and successful vaccination in Iran and significant decrease in the number of HBVs in the current generation of pediatric age group.…”

mentioning

confidence: 64%

Pediatric Hepatocellular Carcinoma, a Single Center Study from the South of Iran: Case Series

et al. 2017

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma is a rare tumor in children, thus, there are not many studies regarding clinicopathologic findings of this tumor and no report regarding this tumor in this age group from Iran. Objectives: In this study, we tried to find out the clinicopathologic findings including outcome of hepatocellular carcinoma in the patients under the age of 18. Methods: During the last 10 years (2005 -2016), we collected all hepatocellular carcinoma cases in the affiliated hospitals of Shiraz University of Medical Sciences (as the largest referral center in the South of Iran and the only center of pediatric liver transplantation in the whole country) from the archives of Pathology department. Next all clinical data were subsequently extracted from the patients' hospital charts. Results: We collected 30 cases of hepatocellular carcinoma with the age range of 9 months to 18 years with no significant sex preference. All of the patients, except 3, showed abnormal levels of AFP. The most common underlying cause of liver tumorigenesis was type I tyrosinemia. Conclusions: Hepatocellular carcinoma in children is a rare tumor and is mostly secondary to an underlying liver disease, which is tyrosinemia in our center. Hepatitis B related hepatocellular carcinoma is rare in our country, which seems to be related to successful early neonatal vaccination against this viral disease. This tumor has a poor outcome in children and without liver transplantation, has a very short survival rate.

show abstract

mentioning

confidence: 64%

Pediatric Hepatocellular Carcinoma, a Single Center Study from the South of Iran: Case Series

et al. 2017

View full text Add to dashboard Cite

show abstract

“…HCC is the second most common hepatic malignancy in children and accounts for less than 0.5% of all pediatric cancer [34]. An estimated 0.5-1.0 cases per million children is the reported relative frequency for HCC [35].…”

Section: Hepatoblastoma and Hepatocellular Carcinomamentioning

confidence: 99%

Alpha-Fetoprotein in Malignant Pediatric Conditions

Houwelingen¹,

Sandoval²

2016

Proof and Concepts in Rapid Diagnostic Tests and Technologies

View full text Add to dashboard Cite

Abnormal serum α-fetoprotein (AFP) levels are frequently observed in common disorders such as spina bifida or Down's syndrome in the fetus and cancer in children and adults. The focus of this chapter summarizes on the role of serum α-fetoprotein (AFP) as a useful biomarker in malignant pediatric tumors. The fetal yolk sac and liver generate high levels of AFP during gestation and decline over the next 12 months of infancy, and only trace amounts are detected in childhood. As a result, persistent elevation of AFP correlates with a number of select pediatric malignant conditions. Serum AFP is overexpressed in a considerable fraction of germ cell tumors (GCTs), hepatoblastoma (HB), and hepatocellular carcinoma (HCC). We provide the reader with a review of AFP as a useful specific marker for the diagnosis, management, and followup in select pediatric cancers.

show abstract

“…Other combination regimens include cisplatin plus doxorubicin with response rates 18 to 49 percent (Lee et al, 2004;Czauderna et al, 2002), cisplatin, mitoxantrone, and continuous infusion 5-FU with objective response rates 24 to 27 percent in two different studies (Yang et al, 2004;Ikeda et al, 2005), cisplatin, epirubicin and infusional 5-FU with a response rate 15 percent (Boucher et al, 2002;) cisplatin, doxorubicin plus capecitabine with a response rate of 24 percent (Park et al, 2006).…”

Section: Gemcitabine and Cisplatinmentioning

confidence: 99%